Trial reportDiabetes, obesity & metabolism2022
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial.
Trial report in Diabetes, obesity & metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01131676 (A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773), which is not on this map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Effects of sodium-glucose cotransporter-2 inhibitors on serum urate levels and gout in patients with and without type 2 diabetes: a systematic review and network meta-analysis.International journal of clinical pharmacy · 2025Pooled it
- Sodium-glucose cotransporter-2 inhibitors use and the risk of gout: a systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- Combination therapy with vitamin E and ertugliflozin in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a randomized clinical trial.Irish journal of medical science · 2025Trial
- Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Trial
- Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.European heart journal · 2022Trial
- Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF.European journal of heart failure · 2022Trial
- Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial.Diabetes, obesity & metabolism · 2022Trial
- SGLT2 inhibitors preserve serum chloride in non-diabetic CKD: a propensity-matched and LASSO regression analysis.Renal failure · 2026Article
- Effects of Losartan, Empagliflozin, and Their Combination on Uric Acid Concentrations in People With Type 2 Diabetes.Kidney medicine · 2026Article
- Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Gout Risk: A Population-Based Comparative Cohort Study With Genetic Evidence From Mendelian Randomisation.Diabetes, obesity & metabolism · 2026Article
- A Prospective Study on the Metabolic and Hormonal Outcomes of SGLT2 Inhibitor Combination Therapy With and Without Metformin in Newly Diagnosed Type 2 Diabetes Mellitus.Biomedicines · 2026Article
- Disentangling Uric Acid and Renal Pathways in SGLT2 Inhibitor Effects After Acute Myocardial Infarction: A Retrospective Mediation Analysis.Biomedicines · 2026Article
- The effect of empagliflozin on renal outcomes compared to sitagliptin with type 2 diabetes: target trial emulation using electronic medical records.International journal of clinical pharmacy · 2026Article
- Effect of sodium-glucose cotransporter-2 inhibitors on uric acid in patients with heart failure and preserved ejection fraction: a retrospective analysis in real word.BMC cardiovascular disorders · 2026Article
- Metabolic Profiling of the EmDia Cohort by LC-MS Reveals Empagliflozin-Intake Associated Regulation of 1,5-anhydroglucitol and Urate.Proteomics · 2026Article
- Innovative insights into the effects of a high-sucrose diet on pancreatic health and the therapeutic role of empagliflozin in type 2 diabetes: An experimental study.Animal models and experimental medicine · 2025Article
- Could Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists Play a Role in Gout Treatment?Pharmaceutics · 2025Review
- Asymptomatic Hyperuricemia and the Kidney: Lessons from the URRAH Study.Metabolites · 2025Review
- Comparison of the efficacy of antidiabetic agents in type 2 diabetes with MASLD: a network meta-analysis.Frontiers in endocrinology · 2025Article
- Serum uric acid reduction through SGLT2 inhibitors: evidence from a systematic review and meta-analysis.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the effect of empagliflozin on uric acid (UA) levels, antigout medication and gout episodes in the EMPA-REG OUTCOME trial (NCT01131676). MATERIALS AND
methodsA total of 7020 patients with type 2 diabetes (T2D) were randomized to either empagliflozin (10 or 25 mg) or placebo. The effects of empagliflozin versus placebo on UA concentration were assessed using mixed linear models. A composite outcome of new prescription of antigout medication or gout episode was studied with Cox proportional hazards models.
resultsEmpagliflozin reduced serum UA levels versus placebo: week 52 adjusted mean treatment difference = -0.37 (95% confidence interval [CI] -0.42, -0.31) mg/dL; this was more pronounced in patients with baseline UA ≥ 7.0 mg/dL versus <7.0 mg/dL: week 52 adjusted mean treatment difference = -0.56 (95% CI -0.68, -0.43) and -0.30 (95% CI -0.37, -0.24) mg/dL, respectively. Among 6607 patients not taking antigout medications at baseline, 5.2% had a gout episode or initiated antigout treatment versus 3.6% in the placebo and empagliflozin groups, respectively: hazard ratio 0.67 (95% CI 0.53, 0.85; P = 0.001). Both components of the composite outcome contributed to the reduction with empagliflozin in the composite. Risk reduction was similar with both empagliflozin doses.
conclusionsEmpagliflozin reduced UA levels and the composite of gout episodes or prescription of antigout medication. These clinically important findings expand the utility of empagliflozin as a potential antigout treatment in patients with T2D, beyond its well-established cardio-renal benefits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.